Media ReleasesImmutep

View All Immutep News


Immutep Announces New Data from Ongoing TACTI-mel Study in Unresectable or Metastatic Melanoma Presented at the 4th Annual ICI Europe Summit

SYDNEY, AUSTRALIA – November 27, 2018 – Immutep Limited (ASX:IMM; NASDAQ:IMMP) ("Immutep“ or “the Company“), announces new data from its ongoing TACTI-mel Phase I clinical trial is being presented at the 4th Annual ICI Europe Summit in Berlin, Germany by Dr. Fre´de´ric Triebel, Immutep’s Chief Scientific Officer and Chief Medical Officer. The study is evaluating the combination of eftilagimod alpha (“efti” or “IMP321”), Immutep’s lead product candidate, in combination with anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in 24 patients with unresectable or metastatic melanoma.

The multi-center, open-label clinical trial includes four cohorts of six patients each testing different dosages of efti, including 1 milligram (mg), 6 mg and 30 mg, in combination with pembrolizumab. This latest data includes more mature data from the first three cohorts (part A, the dose escalation part of the study) where the combination treatment begins at cycle 5 of pembrolizumab treatment and the first efficacy data from the fourth cohort (part B) where the combination treatment is administered to patients from the beginning of cycle 1, day 1 of pembrolizumab treatment.


For further information please download PDF attached:
Download this document